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funded programs like Medicaid. Objective of this study was to
review published studies that evaluate the impact of Medicaid
formularies, and to assess the perspective that was adopted 
for such evaluations. METHODS: Searches were performed in
several scientiﬁc and business databases along with other rele-
vant health policy journals and websites. The search strategy
involved an incremental focus using a tiered approach, narrow-
ing search returns down to the speciﬁc inclusion criteria with
multiple combinations of search terms. Selected articles were
reviewed to assess the perspective adopted based on key mea-
surement parameters used in evaluation of the impact.
RESULTS: Twenty studies were selected for the review. All
studies used a pre-post or a time-series research design. Three
studies utilized pooled multi-state data, two studies included a
second state’s Medicaid population as a control group, and the
remaining were studies of single state Medicaid populations. 
All studies evaluated direct impacts of a formulary strategy on
drug and program costs. Three studies additionally investigated
broader second order effects on physician, outpatient and hos-
pital utilization. None of the evaluations included estimates of
indirect costs related to the positive or negative impact of for-
mularies on morbidity, mortality and consequent productivity of
Medicaid beneﬁciaries. Therefore, the true impact of formularies
in these evaluations remain unclear. CONCLUSION: Findings of
the literature review of Medicaid formulary evaluations suggest
that such a societal perspective has not been widely adopted, and
can be a valuable option for future evaluations.
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OBJECTIVE: There is an increasing interest in pharmacoeco-
nomics among physicians. However, as can be seen from multi-
ple examples, the concept is prone for abuse and misuse. In this
study we evaluated the curriculum of the Turkish medical
schools. We looked at whether they have any formal pharma-
coeconomic lectures or they are planning on introducing phar-
macoecononmics lectures within the pharmacology, clinical
pharmacology or other courses. METHODS: A questionnaire
was prepared to evaluate the pharmacoeconomics education at
35 Medical Schools in Turkey. We got in contact with the head
of the Pharmacology Departments either by phone or by face to
face interviews. The questionnaire was composed of questions
regarding the presence of pharmacoeconomics lectures; i.e. if
already in curriculum, at which year, and for how many hours.
If no pharmacoeconomics lecture exists, is there any intention of
including it in the curriculum. RESULTS: We got replies from 27
(77%) of the Pharmacology Departments. Pharmacoeconomy
lecture is currently given only at two niversities (Ankara,
Atatürk). All but two of the other departments communicated
that pharmacoeconomics lectures will be given in the future.
CONCLUSION: Pharmacoeconomics is an important part of
clinical pharmacology. However the concept is not part of the
medical school curriculum in most universities. There is a trend
towards giving pharmacoeconomics classes at fourth or ﬁfth year
within clinical pharmacology lectures. Even though most of the
pharmacology departments informed that they are going to
include pharmacoeconomics into the curriculum, currently prac-
ticing physicians lack the necessary knowledge. In our opinion,
in addition to the inclusion of pharmacoeconomics in the
medical school curriculums, special programs are also required
for physicians who had not had a formal pharmacoeconomic
course during their undergraduate education. There is an increas-
ing responsibility for pharmacology/clinical pharmacology
departments to take a role in such programs.
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OBJECTIVE: Industrial organization economics theory sug-
gested ﬁrms may over- or under-advertise to deter or accommo-
date entry depending on how advertising affects the proﬁts of
competitors, and if the competing products are strategic substi-
tutes or complements. The objective of this study was to deter-
mine if this theory holds for pharmaceutical products. Such
information would increase policy makers’ understanding of
how advertising affects competition when considering advertis-
ing regulations. METHODS: Data on products for eight therapy
areas (asthma, migraine, obesity, Parkinson’s disease, seizure,
depression, dyslipidemia, and gastric and duodenal ulcer) from
January, 1995 to December, 2001 were analyzed on a quarterly
basis. Multivariate analyses were performed to examine the
strategic relationship between advertising expenditures and
product sales. Changes in an existing product’s advertising
expenditure in the period after new product entry were exam-
ined using time-disease ﬁxed-effects regression, by controlling for
the type of new entrants (the presence of creative entrants, uncre-
ative entrants or both in the same period), patent life, and market
share. Creative entrants were new products with novel pharma-
cological mechanisms of action that were different from that of
existing products. Uncreative entrants included me-too drugs
and generic products. Advertising expenditure and sales data
were obtained from Scott-Levin Market Research Audit. Patent
and product entry information were from published references.
RESULTS: Multivariate analyses showed competing pharma-
ceutical products were strategic complements and sales of new
entrants increased with existing product’s advertising expendi-
ture, although these relationships were not statistically signiﬁ-
cant. There were no statistically signiﬁcant changes in advertising
expenditure in response to any types of new product entry. CON-
CLUSION: The strategic effect of advertising on market com-
petitiveness was weak and not signiﬁcant. No evidence was
found that pharmaceutical ﬁrms would use advertising as a
strategic tool to deter or accommodate entry. These results did
not support regulating pharmaceutical advertising based on anti-
competitive grounds.
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OBJECTIVES: To model the effect of mail order vs. community
pharmacy on drug utilization and drug product cost in a 
Medicaid population. METHODS: Drug treatments initiated
between August, 2000 and July, 2001 were retrieved. Drug treat-
ments with at least two claims and 60 days of supply, and an
adherence ratio of 0.5 were included in the study. In the base-
line scenario, utilization in mail order was modeled using the uti-
lization in community pharmacy, and assuming that the ﬁrst
prescription was dispensed in community pharmacy, and suc-
cessive prescriptions were dispensed as 90-day supply in mail
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order pharmacy. Dispensing fees were deducted from the com-
munity pharmacy cost to estimate the average drug product cost
per day supply. Drug product cost per day supply was multiplied
by the modeled days supply in mail order to estimate the drug
product cost in mail order. The effect of mail order was estimated
by therapeutic class. A multivariate sensitivity analysis was per-
formed. RESULTS: In the period August, 2000 to July, 2001, 4.1
million drug treatments were initiated; of those, 758 thousand
(18.7%) were selected based on the criteria set in the study for
use of mail order. The use of mail order resulted in 6.3% more
days supply and 6.4% more drug product cost than in commu-
nity pharmacy. The therapeutic classes with the lowest increase
in drug product cost were immunosuppressants (4.8%), cardio-
vascular agents (4.9%) and smooth muscle relaxants (5.5%).
Results were sensitive to changes in the assumptions of minimum
day’s supply of the treatment, adherence rate, and the number
of ﬁll in community pharmacy before mail order was initiated.
CONCLUSIONS: Mail order pharmacy increased drug utiliza-
tion. Mail order could lead to an increase in Medicaid drug
expenditures if the mail order reimbursement formula does not
discount the effect of increased drug utilization.
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OBJECTIVES: This research determines the effects of higher
brand and generic drug copays on drug utilization, the price elas-
ticity of drug demand in a commercially insured population.
METHODS: Drug utilization variables and health status indica-
tors are computed separately for each full year of enrollment
under a speciﬁc copay structure. Fixed effect estimation is per-
formed with the ﬁrst difference estimator to obtain the marginal
effect of copay change on net drug cost and number of pre-
scriptions. Data were provided by a major West Coast pharmacy
beneﬁt management company. The sample consists of all insur-
ance claims for employees, their spouses, and their dependents,
under age 65, who were enrolled continuously for two years.
Enrollees worked in a small California ﬁrm—a ﬁrm with 2–50
employees—that offered only one health plan. The ﬁnal sample
has 30,824 enrollees working in 4554 small ﬁrms. RESULTS:
Higher generic drug copay leads to a reduction in number of 
prescriptions (-0.23; p < 0.0001) and total net cost to the insurer
(-$7.06; p < 0.0001). Higher brand copay only results in lower
total net cost to the insurer (-$2.5; p < 0.0001). The generic 
price elasticity for total net cost is -0.16, and brand price elas-
ticity for total net cost is -0.11. CONCLUSION: Enrollees
decrease their drug use when faced with higher copays and health
plans can signiﬁcantly reduce their outlays on drugs by raising
drug copays.
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OBJECTIVES: To document the current level of need for med-
ications among currently underinsured elderly individuals and to
describe the medical conditions that lead to hospitalizations in
this group. METHODS: This study utilizes a unique data base
containing “quasi-claims” data on 5303 Maryland residents 65
years of age or older who received free drugs from Patient Assis-
tance Programs (PAPs). MEDBANK, a program that helps low-
income individuals cope ﬁnancially by assisting them in applying
for free-drug programs, maintains an internal data base on the
drugs requested and those that were received. This data base
makes it possible to identify the drugs that were requested and
received by this group for which no claims data base exists.
Elderly MEDBANK recipients are then matched to the state of
Maryland inpatient discharge data base to identify the diagnoses
for which these individuals were hospitalized. RESULTS: The
most frequently requested drugs were cardiovascular agents,
which account for 42% of all requests. Commensurate with that
result, we ﬁnd that the top primary diagnosis for hospitalizations
of this population was for diseases of the circulatory system. The
least accessible drugs were anti-infective systemic agents, for
which patients received only 34% of their requests. Overall,
MEDBANK recipients received 59% of the drugs requested. 
The median patient received about two-thirds of their requests,
while the median number of drugs requested and received,
respectively, were six and three. CONCLUSIONS: PAPs allowed
Maryland Medicare eligible individuals to receive only 59% of
the drugs they requested, highlighting the need for additional
coverage.
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OBJECTIVE: The pharmacy’s recorded days supply variable is
frequently used in outcomes research to estimate a prescription’s
intended period of use, but little is published on factors that
might inﬂuence its validity. We examined the effect of a change
in copayment structure on the accuracy of the days supply ﬁeld
of a prescription records database. METHODS: Prior to January
1, 2002, Kaiser Permanente Northwest enrollees were able to
obtain a 90-day supply of medication for one copay. After this
date, a copay was required for each 30-day medication supply.
We collected dispensing data for oral antidiabetic medications
from January 1, 1996-December 31, 1997 (90-day copay), and
from January 1, 2002–December 31, 2002 (30-day copay).
Accuracy of the recorded days supply variable was compared to
a gold standard (calculated by pharmacist (KS) interpreting 
each prescription’s directions for use. RESULTS: There were
3155 and 1495 records in the 90-day copay and 30-day copay
periods, respectively. The mean difference (±SD) between gold
standard and recorded days supply under the 90-day copay was
0.92 days (±24.3); 72.8% were in complete agreement, 10.7%
were +1 to +30 days different, 5.2% were -1 to -30 days dif-
ferent, maximum range of -200 to 370 days different. The 
mean difference (±SD) under the 30-day copay was -0.33
(±10.8) days; 88.3% were in complete agreement, 9.1% were +1
to +30 days different, and 5.1% were -1 to -30 days different,
range of -90 to +90 days different. CONCLUSION: After
requiring additional copayments for a 90-day supply, the phar-
macy’s recorded days supply was more likely to be in agreement
with the directions for use. Both pharmacy staff and enrollees
may have contributed to the improvement by verifying that
copays were accurate. When both provider and enrollee have a
ﬁnancial interest, prescription days supply data may be more
accurate.
